Lifog

Latanoprost, the active ingredient in Lifog, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the treatment of primary open‑angle glaucoma and ocular hypertension in adult patients. The medication works by enhancing fluid outflow, thereby helping to preserve visual function.

GNH USA supplies Lifog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions.

Latanoprost is used to lower intra‑ocular pressure in glaucoma‑related conditions.

- Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma. - Secondary open‑angle glaucoma (including pseudoexfoliative): improves aqueous outflow to control pressure.

Latanoprost may cause ocular and peri‑ocular adverse reactions, which are classified by frequency.

Common Side Effects: - Eye redness: transient hyperemia of the conjunctiva. - Increased eyelash growth: longer, thicker lashes may appear. - Iris pigmentation: gradual darkening of the iris color. - Eye irritation: burning or stinging sensation after instillation. - Blurred vision: temporary reduction in visual clarity.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, itching, or rash around the eye. - Corneal edema: swelling of the cornea that can affect vision. - Paradoxical rise in intra‑ocular pressure: unexpected pressure increase. - Vision loss: rare but possible loss of visual acuity.

When prescribing Latanoprost, clinicians should observe several precautionary measures to ensure safety and efficacy.

- Monitor intra‑ocular pressure: assess IOP regularly after initiation. - Contraindicated in active ocular infection: avoid use during conjunctivitis or keratitis. - Caution in patients with a history of uveitis: may exacerbate inflammation. - Avoid contact lens wear for 15 minutes after instillation: reduce drug absorption on lens. - Use with caution in herpetic eye disease: may trigger reactivation. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogues: additive effect may increase risk of ocular side effects. - Combination with ocular anesthetics containing preservatives: may enhance corneal irritation.

Moderate Interactions (Monitor Closely): - Co‑administration with non‑steroidal anti‑inflammatory eye drops: may alter prostaglandin metabolism. - Use together with beta‑blocker eye drops: additive intra‑ocular pressure reduction may cause hypotony. - Systemic carbonic anhydrase inhibitors: potential for increased ocular irritation. - Anticholinergic eye medications: possible reduction in Latanoprost efficacy.